Wuhan Hvsen Biotechnology Co Ltd Market Cap ($509.35 Million)
Market Cap & Net Worth: Wuhan Hvsen Biotechnology Co Ltd (300871)
Wuhan Hvsen Biotechnology Co Ltd market cap. Wuhan Hvsen Biotechnology Co Ltd (SHE:300871) has a market capitalization of $509.35 Million (CN¥3.48 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #11832 globally and #3359 in its home market, demonstrating a 3.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Hvsen Biotechnology Co Ltd's stock price CN¥17.25 by its total outstanding shares 201784357 (201.78 Million). Also see Wuhan Hvsen Biotechnology Co Ltd (300871) cash flow conversion for how efficiently the company converts equity into cash flow.
Wuhan Hvsen Biotechnology Co Ltd Market Cap History (2020–2026)
Wuhan Hvsen Biotechnology Co Ltd market cap history from 2020 to 2026. Data shows change from $737.16 Million to $509.35 Million (-12.21% CAGR). Check Wuhan Hvsen Biotechnology Co Ltd (300871) share price today for real-time trading data and today's change.
Wuhan Hvsen Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Hvsen Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Wuhan Hvsen Biotechnology Co Ltd (300871) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.36x
Wuhan Hvsen Biotechnology Co Ltd's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.42x
Wuhan Hvsen Biotechnology Co Ltd's market cap is 2.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $737.16 Million | $777.46 Million | $150.16 Million | 0.95x | 4.91x |
| 2021 | $795.20 Million | $996.22 Million | $132.87 Million | 0.80x | 5.98x |
| 2022 | $579.39 Million | $1.02 Billion | $52.71 Million | 0.57x | 10.99x |
| 2023 | $418.15 Million | $1.02 Billion | $16.78 Million | 0.41x | 24.92x |
| 2024 | $297.05 Million | $1.20 Billion | -$20.16 Million | 0.25x | N/A |
| 2025 | $612.10 Million | $1.68 Billion | $253.16 Million | 0.36x | 2.42x |
Competitor Companies of 300871 by Market Capitalization
Companies near Wuhan Hvsen Biotechnology Co Ltd in the global market cap rankings as of November 5, 2026. Also see 300871 total assets for a full breakdown of the balance sheet.
Key companies related to Wuhan Hvsen Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Wuhan Hvsen Biotechnology Co Ltd (2020–2026)
Market capitalization of Wuhan Hvsen Biotechnology Co Ltd from 2020 to today. Between 2020 and today, Wuhan Hvsen Biotechnology Co Ltd's market cap moved from $737.16 Million to $ 509.35 Million, with a yearly change of -12.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥509.35 Million | -16.79% |
| 2025 | CN¥612.10 Million | +106.06% |
| 2024 | CN¥297.05 Million | -28.96% |
| 2023 | CN¥418.15 Million | -27.83% |
| 2022 | CN¥579.39 Million | -27.14% |
| 2021 | CN¥795.20 Million | +7.87% |
| 2020 | CN¥737.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Wuhan Hvsen Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $509.35 Million USD |
| MoneyControl | $509.35 Million USD |
| MarketWatch | $509.35 Million USD |
| marketcap.company | $509.35 Million USD |
| Reuters | $509.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildi… Read more